MabPlex

Executive Summary

MabPlex is a China-based biologics CDMO specializing in monoclonal antibodies and complex proteins, offering integrated services from cell line development to commercial GMP manufacturing. Founded in 2013 and located in Yantai, the company employs 500-1000 staff and serves both Chinese biotechs and international partners seeking cost-effective, high-quality production capacity in Asia-Pacific. As a private platform company, MabPlex benefits from the global trend of biopharma outsourcing, particularly for biosimilars and innovative biologics. The company's competitive edge lies in its ability to deliver rapid development timelines at lower costs compared to Western CDMOs, while maintaining compliance with international regulatory standards. With the increasing demand for biologics manufacturing in Asia, MabPlex is well-positioned to capture market share, though it faces competition from larger regional players like WuXi Biologics. Financial details remain undisclosed, but the company's estimated valuation and growing client base suggest steady expansion. Key risks include regulatory changes, client concentration, and pricing pressure.

Upcoming Catalysts (preview)

• Q3 2026Completion of new commercial-scale manufacturing facility in Yantai80% success
• Q3 2026Strategic partnership with a top-20 global pharmaceutical company for biosimilar production50% success
• TBDExpansion into cell and gene therapy CDMO services40% success